drugset
drugset / Trial / NCT05282446

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

NCT05282446 ↗

Phase 1 Completed 37 enrolled Inversago Pharma Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

INV-202-CL-105 is a phase 1B study to examine the safety and tolerability, as well as the pharmacokinetics (PK) pharmacodynamic (PD) effects of INV-202 in subjects with metabolic syndrome over 28 days.

Timeline

Start
2022-03-01
Primary completion
2022-09-11
Completion
2022-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject INV-202 Unknown 25 mg Oral

Indications

metabolic syndrome X